Background: Chronic rhinosinusitis (CRS) significantly affects health-related quality of life (HRQoL). Few multinational observational studies have evaluated the impact of CRS with nasal polyps (CRSwNP) on patients' HRQoL. This study aimed to assess HRQoL outcomes (including analyses by disease severity and impact of comorbidities and refractory disease) in CRSwNP patients from a large European database.
Introduction
Chronic rhinosinusitis (CRS), an inflammatory condition of the nose and sinuses, is a common medical condition that affects approximately 11% of adults in Europe (1) and 12% of adults in the USA (2) . CRS has a significant impact on health-related quality of life (HRQoL) (3, 4) and is associated with substantial healthcare (5) (6) (7) and productivity costs (8) . In adults, CRS with or without nasal polyps (CRSwNP and CRSsNP, respectively) is defined in the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) guidelines as the presence (for ≥ 12 weeks) of 2 or more symptoms, 1 of which is either nasal blockage/ obstruction/congestion or nasal discharge (anterior or posterior nasal drip), with facial pain or pressure and/or reduced or lost sense of smell (9) . In the majority of patients in Western Europe, CRSwNP is an idiopathic and eosinophilic form of CRS (10) that is characterised by a type 2 helper T cell (Th2) inflammatory profile (11, 12) . Compared with CRSsNP, CRSwNP is more often associated with symptoms of rhinorrhoea and decreased sense of smell (13) and with comorbid conditions such as asthma and non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) (14) (15) (16) . The prevalence of CRSwNP is estimated between 2.1% (France) (17) and 4.4% (Finland) (18) in Europe and 4.2% in the USA (19) , 2.5% in South Korea (20) , and 1.1% in China (21) .
There are few large, multinational, observational studies of the burden of CRSwNP on patients' lives or of the impact of disease severity, comorbidities, and refractory disease on HRQoL.
The EPOS 2012 guidelines (9) recommend treatment based on disease severity for all adult patients.
The Global Allergy and Asthma European Network (GALEN) is a network of excellence of the leading European clinical and research facilities in allergology and asthma (22) . It represents 20
European countries and includes 2 European societies, 60 collaboration centres, 27 research institutes, and 2 small-to-mediumsized enterprises (defined as legally independent companies with ≤ 500 employees). The GALEN Rhinosinusitis Cohort, a component of the GALEN network, is a European cross-sectional cohort that was established to enhance and advance research on CRS (12, 23, 24) .
The objective of this study was to assess HRQoL outcomes in patients with CRSwNP who participated in the GALEN Rhinosinusitis Cohort. Patients' HRQoL was assessed using the generic HRQoL questionnaire, the 36-Item Short-Form Health Survey (SF-36), and SF-36 scores were compared between patients with CRSwNP and population norms and between patient subgroups. From this large cohort, we were able to assess the impact of CRSwNP and the effect of disease severity, comorbidities (asthma, N-ERD), and refractory disease on patients' HRQoL.
Materials and methods

Study design
The GALEN Rhinosinusitis Cohort study was a cross-sectional observational study set up within the GALEN consortium to identify inflammatory endotypes, the natural course of the disease, and the impact of the disease on HRQoL in patients with CRS. The study included patient-and clinician-reported data as well as biomarker data from participants. The results of measurement of inflammatory biomarkers have already been published (12) . Patients were included from 9 European centres in Belgium, Finland, Germany, the Netherlands, Poland, Spain, Sweden, and the UK between 25 April 2007 and 7 December 2009. The recruitment of patients for the GALEN Rhinosinusitis Cohort and the collection of patient demographic and clinical data have been previously described (23) .
Key inclusion criteria
This analysis focused on adult patients from the GALEN Rhinosinusitis Cohort who had CRSwNP defined according to the EPOS 2007 guidelines (14) . Therefore, symptoms had to include nasal blockage/obstruction/congestion or nasal discharge, facial pain or pressure, and reduced or lost sense of smell, and must have been present for ≥ 12 weeks with endoscopic signs or radiographic changes and without complete resolution.
Patient-reported and clinical outcomes
In addition to socio-demographic patient information, patientreported outcomes (PROs) and clinical outcomes from the GA-LEN Rhinosinusitis Cohort database were included in this study.
PRO measures included the HRQoL scale, the SF-36 (version 1), and the disease severity visual analogue scale (VAS) (14) . The SF-36, a generic HRQoL questionnaire, yields an 8-scale profile of functional health and well-being scores (25, 26) . Its individual domains are physical functioning, role -physical, bodily pain, general health, vitality, social functioning, role -emotional, and mental health (26) . The SF-36 also provides psychometrically based physical and mental health summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS) (26) . The VAS, a measure of disease severity, was used to assess impairment due to CRS (0-10 cm; 0 = no problem, 10 = worst imaginable problem) (14) . Data on previous sinonasal surgeries and comorbidities were documented. The methods for diagnosis of comorbidities in the GALEN Rhinosinusitis Cohort have been described (23) . Briefly, a yes/no response from patients was recorded by the investigator for each comorbidity. Allergic status was based on medical history and confirmed by a skinprick test (using the pan-European allergen panel), a blood assay (radioallergosorbent test), or allergen provocation.
Statistical analyses
Data from patients with CRSwNP and each subgroup (patients with and without comorbidities, with disease of different severities, and with refractory disease) were analysed for descriptive comparison. Qualitative variables are summarised by counts and and descriptive results of the GALEN Rhinosinusitis Cohort study have been described by Khan and colleagues (23) . 
Impact of CRSwNP on HRQoL
Impact of asthma and N-ERD on HRQoL
Patients with CRSwNP and comorbidities such as asthma (n = 135) or N-ERD (n = 11) had significantly lower mean SF-36 PCS (with asthma p < 0.0001; with N-ERD p < 0.001) and MCS scores (with asthma p < 0.0001; with N-ERD p = 0.014) compared with population norms, and the differences between groups were clinically meaningful (PCS difference −6.9 for patients with asthma, −9.2 for patients with N-ERD; MCS difference −4.4 for patients with asthma, −7.2 for patients with N-ERD) ( Figure 2A ).
Compared with CRSwNP patients without asthma (n = 147), percentages; quantitative variables are summarised by means, medians, and range and standard deviation (SD), with the number of observations for each variable calculated. The denominator for percentages of patients is the total number of observations (N). Study participants with fewer than 2 completed variables were excluded from the analyses. The analyses used observed data. No data imputation was done. Statistical tests of difference were 2-sided, with a global type I error α of 5% using a Student's t-test of 1 sample for the difference between the mean of a sample and another mean and of 2 samples for the difference between means. The minimal clinically important difference (MCID) was defined according to the SF-36 guidelines: ≥ 2 points for PCS and ≥ 3 points for MCS scores (26) . The MCID for each of the 8 individual domains (≥ 8.3 points) was defined using Cohen's rule of thumb (27) .
Differences were evaluated using the Student's t-test of 1 sample and the MCID for mean SF-36 scores between patients with CRSwNP and age-adjusted population norms (28) . The UK population norm was used because it includes age as a variable.
Previous studies have demonstrated that SF-36 questionnaires are similar across European countries, not only in scores but also in structural content (29, 30) . It was therefore decided that UK population norms were an adequate comparison.
Differences between CRSwNP patients with and without comorbidities (asthma, N-ERD, or both conditions), with different disease severity (VAS), or with refractory disease (those who had undergone previous sinonasal surgery) and population norms were evaluated using the Student's t-test of 1 sample and the MCID for mean SF-36 PCS and MCS scores. Differences in mean SF-36 PCS and MCS scores between CRSwNP patients with and without comorbidities, between patients with and without history of surgery, and in patients with mild, moderate, or severe disease were also evaluated using the Student's t-test of 2 samples and the MCID.
Spider plots (31, 32) were used to graphically depict the difference between the group mean score and the adjusted population norm mean for individual domain scores stratified by absence or presence of comorbidity, VAS disease severity score, and history of sinonasal surgery.
The statistical programmes used for the analyses included R and TANAGRA (33, 34) .
Results
Patient demographics and characteristics
A total of 445 patients with CRSwNP were included from 9
European centres participating in the GALEN network. The demographics and characteristics of the overall population are shown in Table 1 . In the overall CRSwNP population, the mean age was 46.8 years; 58.6% were male; the mean time since diagnosis was 10.5 years; and the mean symptom duration was 12.8 years. The mean disease severity VAS score was 6.4 (SD 2.8), (35) .
C o r r e c t e d P r o o f
CRSwNP patients with comorbid asthma had a significantly lower PCS score (p = 0.002); this difference was also clinically meaningful (−3.7). The presence of comorbid N-ERD also decreased the PCS score; this difference was statistically significant (p = 0.031) and clinically meaningful (−5.9) compared with patients with CRSwNP without asthma (Figure 2A ). Compared with CRSwNP patients with asthma, CRSwNP patients with N-ERD had lower PCS scores; this difference was, however, not statis-tically significant (p = 0.484) ( Figure 2A ). (p = 0.046), bodily pain (p = 0.046), general health (p = 0.0017), vitality (p = 0.0013), and social functioning (p = 0.0042). 
Impact of refractory CRSwNP on patients' HRQoL, defined by sinonasal surgery history
Sinonasal surgery is normally reserved for patients who are non-responsive to optimal medical treatment or have recurrence after surgery (36) . Recurrence of nasal polyps (NPs) has been reported at rates from 15% to nearly 50% in the general population during 3 years of follow-up (37) .
In this cohort, CRSwNP patients with or without a history of sinonasal surgery had significantly lower mean SF-36 PCS (−6.3 and −3.5, respectively; p < 0.0001 for both) and MCS scores (−4.1
[p < 0.0001] and −2.6 [p = 0.005], respectively) compared with those of population norms.
Patients with a history of sinonasal surgery (n = 155), reflecting refractory disease, had a significantly lower mean SF-36 PCS score (−2. 8; p = 0.0168) than those without a history of surgery (n = 183). Differences in MCS scores between patients with and without a history of sinonasal surgery were neither statistically significant nor clinically meaningful ( Figure 3A ).
Patients with CRSwNP without a history of surgery had significantly lower mean scores than population norms in the following individual SF-36 domains: physical functioning (p = 0.02), role -physical (p = 0.002), bodily pain (p = 0.0002), roleemotional (p = 0.005), mental health (p = 0.006), general health, and social functioning (p < 0.0001 for both) ( Figure 3B ). These compared with those with 1, there was a further deterioration in PCS score; the impact was both clinically meaningful (−5.5) and statistically significant (p = 0.0042).
Impact of VAS disease severity on CRSwNP patients' HRQoL
CRSwNP patients with a VAS severity score of 0-3 (mild disease, n = 53) had mean PCS and MCS scores similar to or higher than those of population norms ( Supplementary Table 1 ). CRSwNP patients with a VAS score of 3-7 (moderate disease, n = 91) had lower mean PCS and MCS scores than population norms; the difference was statistically significant for the PCS score (p < 0.00001; Supplementary Table 1 ). Patients with a VAS score of 7-10 (severe disease, n = 183) had significantly lower mean PCS and MCS scores compared with population norms (all p < 0.00001; Supplementary Table 1 ).
Compared with patients with mild disease, patients with moderate or severe disease had lower PCS and MCS scores.
The differences in PCS scores were statistically significant and clinically meaningful (moderate vs mild −8.4, severe vs mild −9.1; p < 0.0001 for both). The difference in MCS scores between patients with moderate disease and those with mild disease was not clinically meaningful (−2.9) or statistically significant. By contrast, the difference in MCS scores between patients with severe disease and those with mild disease was clinically meaningful (−8.8) and statistically significant (p < 0.0001) ( Figure 4A ).
Compared with population norms, CRSwNP patients with mild disease (VAS score of 0-3) had similar or higher mean individual domain scores on the SF-36 ( Figure 4B ; Supplementary Table 1) Figure 4B ; Supplementary Table 1 ). Patients with severe disease (VAS score 7-10) had lower individual domain scores compared with population norms; the differences were statistically significant and clinically meaningful for all 8 individual domains (p < 0.00001) ( Figure 4B ; Supplementary Table 1 ). This study focused on HRQoL in patients with CRSwNP because these patients are often reported to have a higher disease burden than those with CRSsNP (38, 39) . NP disease, as described here, includes chronic inflammation of the nose and sinuses (CRS).
Discussion
The negative impact of CRSwNP on patients' HRQoL shown in this study is consistent with that reported for CRS in other studies (3, 38, (40) (41) (42) (43) . Philpott et al. (43) Aspirin sensitivity (N-ERD), compared with aspirin tolerance and NPs, was not reported to have an additional negative impact on HRQoL (44) .
The potential limitations of the present study need to be taken into consideration: this was not an epidemiological study, and the fact that participating centres were large tertiary institutions may have led to an inclusion bias towards patients with higher disease burden and more severe CRSwNP. In addition, as in any questionnaire-based study, the results may have been subject to recall bias. The GALEN Rhinosinusitis Cohort study recruited 187 adults with no history of CRS symptoms (23) , but these patients were not considered an appropriate control group as they were outpatients of ear, nose, and throat clinics of centres participating in the GALEN and, as such, would have had other nasal or sinus disorders. Although the use of age-adjusted UK population norms as controls instead of healthy patients is a potential limitation of our study, previous studies have demonstrated that the SF-36 results are similar across European countries, not only with respect to scores but also to structure (29, 30) . Self-assessed health status measured by the SF-36 resulted in similar scores in 3 European national surveys (UK, Germany, and Italy), indicating the comparability of content of the SF-36 in different translations (29) .
A comparison of algorithms used to rate PCS and MCS scores (PCS-36/MCS-36) based on the SF-36 from the International Quality of Life Assessment project (across 10 different coun-tries) indicated a high degree of similarity within each country between standard and country-specific algorithms (30) . In the absence of age-based SF-36 data from each of the participating European countries, we deemed the UK population norms to provide an adequate comparison. However, of the 8 European countries encompassing the GALEN (Belgium, Finland, Germany, Netherlands, Poland, Spain, Sweden, and the UK), only 5 were included in the comparative analysis by Ware et al. (30) . Three countries, therefore, did not have data that have been shown to be normative.
The strength of the present study is that it consisted of a large cross-sectional cohort of patients recruited throughout Europe and for whom many clinical data and biomarkers (12) 
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